Chronic hepatitis C
Conditions
Interventions
Peginterferon alpha2a or alpha2b plus ribavirin for 48-72 weeks
Sponsors
Research Center for Hepatitis & Immunology, Kohnodai Hospital, International Medical Center of Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with chronic hepatitis C of genotype 1 and high viral load who newly start peginterferon and ribavirin combination therapy
Exclusion criteria
Exclusion criteria: 1) Patients taking Sho-sai-koto(herbal medicine) 2) Autoimmune hepatitis 3) Patients with history of interstitial pneumonia 4) Patients with previous history of drug allergy against ribavirin, peginterferon alpha2a (Pegasys), peginterferon alpha2b (Pegintron), or other interferons 5) Patients with previous history of drug allergy against biological products such as vaccines 6) Liver cirrhosis, liver failure or hepatocellular carcinoma 7) Patients with the following laboratory data at the start of peginterferon and ribavirin combination therapy: WBC counts less than 4,000/microliter and Neutrophil counts less than 1,500/microliter; Platelets counts less than 90,000/microliter (peginterferon alpha2a) or 100,000/microliter(peginterferon alpha2b); Hemoglobin levelsless than 12g/dL 8) Women who are pregnant or have its possibility 9) Patients who refuse birth control, including male patients whose patners may have the chance to be pregnant 10) Patients whom the physicians in charge judge their enrollment inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship between targeted SNPs and virological response to peginterferon/ribavirin combination therapy | — |
Countries
Japan
Contacts
Public ContactNaohiko Masaki, M.D.
Kohnodai Hospital, International Medical Center of Japan Research Center for Hepatitis & Immunology
Outcome results
None listed